Acenocoumarol is a short-lived oral anti-coagulant， which， like warfarin， functions by inhibiting vitamin K epoxide reductase. It has higher intrinsic anticoagulant potency than warfarin and phenprocoumon， when evaluated in vitro. Acenocoumarol has a single chiral center that gives rise to two different enantiomeric forms. （R）-（+）-Acenocoumarol has a longer plasma elimination half-life （6.6 hours） and slower plasma clearance （1.9 L/hour）， compared to the （S）-（-）-enantiomer （1.8 hours， 28.5 L/hour）. The R-enantiomer is rapidly absorbed from the gastrointestinal tract with essentially complete oral bioavailability， whereas （S）-（-）-acenocoumarol undergoes extensive first-pass metabolism. Perhaps related to these pharmacokinetic characteristics， （R）-（+）-acenocoumarol is more potent in vivo as an anti-coagulant than the （S）-（-）-enantiomer. As the clearance of acenocoumarol is ~20-fold faster than that for warfarin， the plasma concentrations of acenocoumarol are substantially lower than those for warfarin in patients receiving long-term treatment.
产品描述
An enantiomer of the short-lived oral anti-coagulant acenocoumarol with a longer plasma elimination half-life （6.6 hours） and slower plasma clearance （1.9 L/hour）， compared to the （S）-（-）-enantiomer （1.8 hours， 28.5 L/hour）； rapidly absorbed from the gastrointestinal tract with essentially complete oral bioavailability； more potent in vivo than the （S）-（-）-enantiomer
